Vitamin B2 treatment for keratoconus and corneal thinning
Part of Eyes & vision clinical trials.
This trial tests a treatment called corneal cross-linking (CXL) using vitamin B2 (riboflavin) drops and UV light to strengthen the cornea and slow down thinning. It is for people with keratoconus, post-surgical thinning, or certain corneal infections that are getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be diagnosed with keratoconus, or have thinning of the cornea after eye surgery, or have a progressive corneal infection with thinning.
- Have the cornea thinner than normal but not too thin (thinnest point must be over 400 microns, or over 300 microns if using a special solution).
- Have at least one sign of keratoconus, like a ring in the cornea or a steep curve on your eye scan.
- If you wear contact lenses, you must stop wearing them for a certain time before your eye exam (for example, 1 week for soft lenses, 3 weeks for toric lenses).
- Not be pregnant, nursing, or planning to become pregnant during the study.
- Not have other eye diseases like herpes or severe scarring that could complicate treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether a specific corneal cross-linking system (called PXL-Platinum 330) is safe and effective for people with progressive keratoconus, a condition that makes the cornea thin and bulge. The goal is to slow vision changes and see how well the treatment works in the short term.
This study tests a procedure called corneal crosslinking to slow or stop the progression of keratoconus or corneal ectasia. It might help keep your cornea stable and prevent further vision loss.
This study tests whether treating donor corneal tissue with a special light and vitamin drops (called cross-linking) before a transplant helps improve outcomes for people with keratoconus. If you need a corneal transplant, this could strengthen the donor tissue and potentially reduce the need for future procedures.
This study tests a same-day procedure that strengthens the cornea (the clear front part of the eye) in both eyes using a special light treatment, called cross-linking. It may help slow or stop the progression of keratoconus, a condition where the cornea becomes cone-shaped and causes blurry vision.
This trial studies whether pretreatment with a specific vitamin and ultraviolet light can help a future, high-risk corneal transplant keep its new cornea healthy for longer. It may help people whose corneas already have new blood vessels, which can make transplant results harder.
This Phase 2 study tests how safe and well a corneal cross-linking device (called PXL-Platinum 330) works for people with corneal ectasia (a thinning/steepening of the cornea). If you qualify, the goal is to help stop or slow further worsening of your cornea shape and improve eye stability.
Hear when a new Keratoconus, Unstable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.